RBC Capital analyst Rishi Jaluria maintains NICE (NASDAQ:NICE) with a Outperform and raises the price target from $240 to $265.
6 Analysts Have This to Say About Chemours
Within the last quarter, Chemours (NYSE:CC) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…